Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol and Fluticasone, Atc R03ak11 for the Period June 1St, 2023 - May 31St, 2025

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Pyridostigmine (N07aa02) as Part of a So-Called Open House Model.

Consulting for the Development of Social and Healthcare Activities and Ict Services

Civil Engineering Works for The Construction of Health Infrastructure

Reproduction of The Normative Documents

Maintenance of Infrastructure and Equipment Including Mobile Clinics

Soft Inventory

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Natalizumab (L04aa23), I.V. Dosage Form as Part of an Open House Model.